Satsuma Pharmaceuticals, Inc. (STSA) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in South San Francisco, CA, United States. The current CEO is John A. Kollins MBA.
STSA has IPO date of 2019-09-13, 25 full-time employees, listed on the NASDAQ Global Market, a market capitalization of $36.47M.
Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can be self-administered with proprietary pre-filled, single-use, and nasal delivery device. Satsuma Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
